BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cedarburg Hauser Promotes John K. Lynch to Chief Scientific Officer


11/6/2012 12:19:58 PM

GRAFTON, Wis., Nov. 6, 2012 /PRNewswire/ -- Cedarburg Hauser Pharmaceuticals (CHP), an experienced contract development and manufacturing organization (CDMO), has announced the appointment of John K. Lynch, Ph.D. as its Chief Scientific Officer (CSO).

Dr. Lynch has served as Cedarburg Hauser's Director of Research and Development for the last three years, where he oversaw development projects and led a staff of scientists. Prior to joining Cedarburg Hauser, Dr. Lynch spent 15 years at Abbott Laboratories, working on a variety of process development and medicinal chemistry projects.

"Dr. Lynch's promotion is well deserved," says Cedarburg Hauser's CEO, Tony Laughrey. "In his time at Cedarburg Hauser, John has successfully led Cedarburg Hauser's research and development efforts and is the ideal person to head-up the company's scientific operations."

"Dr. Lynch is a very talented chemist with a real aptitude for identifying problematic areas in an industrial process and optimizing reaction conditions," added Chuck Boland, Executive Vice President. "These skills have allowed Cedarburg Hauser to save our clients time and money, increasing yields and improving performance."

In his new role, Dr. Lynch will oversee all scientific operations including the process development, R&D and analytical groups. Dr. Lynch holds a Ph.D. in organic chemistry from Harvard University where he studied under Prof. David Evans, and also holds a B.S. from the University of Wisconsin Madison.

About Cedarburg Hauser Pharmaceuticals

Cedarburg Hauser Pharmaceuticals is an experienced contract development and manufacturing organization (CDMO), specializing in small molecule active pharmaceutical ingredients (API) and pharmaceutical intermediates. Cedarburg Hauser leverages a talented group of scientists and supporting -staff, as well as a centralized approach to project management, to ensure on-time and on-budget completion of projects involving the development, scale-up, and manufacturing of complex APIs.

Media Contact:

Bob Forner, Marketing Manager
P: 262-376-1467
Email: bob.forner@cedarburghauser.com

This press release was issued through eReleasesĀ® Press Release Distribution. For more information, visit http://www.ereleases.com.

SOURCE Cedarburg Hauser Pharmaceuticals



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES